Transcatheter Valve Coverage Proposal Reflects Stricter Medicare Environment
This article was originally published in The Gray Sheet
Executive Summary
CMS’ proposed national coverage determination comes only three months after the approval and launch of Edwards Lifesciences’ Sapien, the first transcatheter aortic valve in the U.S. It restricts coverage to FDA-approved indications and includes a coverage-with-evidence-development provision.
You may also be interested in...
Superiority Standard? Groups Bristle At CMS’ Transcatheter Valve Trial Proposal
Some worry that a provision in CMS’ proposed national coverage decision for transcatheter aortic valve replacement devices, which restricts coverage for off-label indications to trials designed to show superiority, signals the agency’s intent to play a more active role in dictating trial designs.
Cardiologists Push Back On Proposed Transcatheter Valve Credentialing Proposals
Clinicians say some of the procedural experience requirements proposed by CMS and societies as prerequisites for conducting transcatheter aortic valve replacements might overly limit access to the technology. ACC has made some revisions to its proposal in response.
The Latest On Transapical: Edwards Talks Up Sapien CAP Data
The non-randomized continued access program, which enrolled 822 transapical patients beyond the original randomized enrollment of 104 transapical patients, tells an improving story for transapical delivery for Sapien.